The Swiss pharma is paying Regor Therapeutics $850 million to buy a pair of prospects it sees as potential successors to blockbuster medicines from Pfizer and Eli Lilly.

Among the investors in Aktis’ Series B round were Bristol Myers Squibb, Eli Lilly and Merck & Co., all of which have expanded their involvement in the radiopharma field.

The high-profile biotech is zeroing in on programs that serve as proof points for its technology, while seeking partners for other assets.

Cheong points to the broad spectrum of patient demographics in the APAC region for creating substantial opportunities for clinical trial sponsors who are keen to meet enrolment targets at an expedited ...

The Food and Drug Administration on Friday approved Regeneron Pharmaceuticals and Sanofi’s inflammatory disease drug Dupixent for a common lung disease. The decision could significantly expand use of ...

While momentous, the approval of Cobenfy could also draw attention to an age-old problem in American healthcare: Will insurance barriers keep patients from getting an effective medicine?

Today, a brief rundown of news from J&J and the FDA, as well as updates from Sage Therapeutics, Roche and Enanta Pharmaceuticals that you may have missed. Recent biotech company acquisitions have put ...

The proceeds will fund a Phase 3 test of a medicine once known as buparlisib and tested by Novartis in dozens of trials. Near the end of the last decade, Novartis had two similar drugs advancing ...

Arch Venture Partners, a prominent creator of biotechnology startups, has raised more than $3 billion for its 13th fund, the firm announced Thursday. The fundraise comes only two years after Arch ...